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Background: A severe encephalitis that associates with auto-antibodies to the NR1 subunit of the NMDA receptor
(NMDA-R) was recently reported. Patients’ antibodies cause a decrease of the density of NMDA-R and synaptic
mediated currents, but the in vivo effects on the extracellular glutamate and glutamatergic transmission are
unknown.
Methods: We investigated the acute metabolic effects of patients’ CSF and purified IgG injected in vivo. Injections
were performed in CA1 area of Ammon’s horn and in premotor cortex in rats.
Results: Patient’s CSF increased the concentrations of glutamate in the extracellular space. The increase was dose-
dependent and was dramatic with purified IgG. Patients’ CSF impaired both the NMDA- and the AMPA-mediated
synaptic regulation of glutamate, and did not affect the glial transport of glutamate. Blockade of GABA-A receptors
was associated with a marked elevation of extra-cellular levels of glutamate following a pretreatment with patients’
CSF.
Conclusion: These results support a direct role of NMDA-R antibodies upon altering glutamatergic transmission.
Furthermore, we provide additional evidence in vivo that NMDA-R antibodies deregulate the glutamatergic
pathways and that the encephalitis associated with these antibodies is an auto-immune synaptic disorder.
Introduction
Antibodies to the N-methyl-D-aspartate (NMDA) sub-
type of glutamate receptor have been identified in a
newly-described encephalopathy [1]. One of the antigens
corresponds to extracellular epitopes of NR1 subunit of
the NMDA receptor (NMDA-R). Typically, patients are
young women with teratoma of the ovary and present-
ing with acute psychiatric manifestations, seizures, dys-
kinesias, hypoventilation and autonomic instability [2].
Early removal of the teratoma followed by plasma
exchange, intravenous immunoglobulins, and corticos-
teroids administration frequently results in neurological
improvement and even full recovery [3].
Recent studies showed that patients’ antibodies cause
a selective and reversible decrease in NMDA-R surface
density and synaptic localization that correlates with
antibody titers. The mechanism of this decrease is selec-
tive antibody-mediated crosslinking and internalization
of the receptors. Furthermore, whole-cell patch clamp
recordings of miniature excitatory postsynaptic currents
in cultured rat hippocampal neurons showed that
patients’ antibodies specifically decreased synaptic
NMDA-R-mediated currents. In contrast, patients’ anti-
bodies did not alter the localization or expression of
other glutamate receptors or synaptic proteins, number
of synapses, dendritic spines, dendritic complexity, or
cell survival. NMDA-R cluster density was also dramati-
cally reduced in the hippocampus of rats infused with
patients’ antibodies, similarly to the decrease of NMDA-
R immunostaining observed in the hippocampus of
autopsied patients [4].
Although patients’ antibodies cause a dramatic reduc-
tion of NMDA-R in vivo, the metabolic effects on the
regulation of glutamate are unknown. An alteration of
the regulation of glutamate would further support the
role of NMDA-R Ab in the pathogenesis of the disorder,
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To test this hypothesis, we conducted experiments in
vivo using microdialysis and determined whether
patients’ CSF antibodies alter the extra-cellular concen-
trations of glutamate. We evaluated the effects
of NMDA-R Ab on the NMDA- and AMPA (alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-
mediated regulation of glutamate. We also investigated
the potential effects of NMDA-R Ab on the glial trans-
port of glutamate. Moreover, we used bicuculline, an
antagonist of GABA-A receptors, in order to unravel a
susceptibility to the blockade of GABA-A receptors fol-
lowing a pretreatment with NMDA-R Ab. In addition,
we studied the effects of infusion of GABA (gamma-
amino-butyric acid) after blockade of the alpha2-delta
subunit of voltage-gated calcium channels (VGCC) with
pregabalin, to assess the responsiveness of the glutama-
tergic synapses to exogeneous GABA when the presy-
naptic release of glutamate was blocked. Finally, we
studied the effects of NMDA-R Ab on nitric oxide
(NO), given the intimate link between the NMDA path-
way and NO in the brain.
Methods
Cerebrospinal fluid and IgG purification
All samples were dialyzed against phosphate buffered
saline, and solutions were used at pH of 7.3. All the
C S Fu s e di nt h ep r e s e n ts t u d yh a dp Ha n dg l u c o s e
levels within the normal range.
Patients’ CSF positive for NMDA-R Ab and purified IgGs
Cerebrospinal fluid (CSF) was obtained from 6 patients
with encephalitis (4 from University of Pennsylvania-
USA and 2 from University of Lyon-France. These last 2
CSF have the reference 9049 and 9052, see later in the
text) associated with antibodies to NR1/NR2 heteromers
of the NMDA receptor. These CSF samples are referred
as patients’ CSF.I na l lc a s e st h eC S Fw a sc o l l e c t e da t
symptom presentation, before any treatment. In addi-
tion, we also used purified IgGs in experiments to con-
firm the results found with patients’ CSF. Purified IgGs
were obtained from the serum of one patient with
NMDA-R-Ab (patient 9052). IgGs were adsorbed to
protein A-Sepharose beads (protein A Sepharose 4 fast
flow; Amersham Biosciences, Saclay, France) and eluted
with sodium citrate (0.5 M, pH 2.5). After neutraliza-
tion, samples were dialyzed overnight at 4°C against
Ringer solution (Fresenius Kabi, Sèvres, France) and
sterilized by filtration with 0.22 m filters as previously
described [5]. The presence of NR1/NR2 antibodies was
demonstrated in all patients as reported earlier[2].
Controls’ CSF and purified IgGs
Controls’ CSF (n = 5) were obtained from 2 patients with
herpes simplex encephalitis (HSE), 2 patients with neuro-
degenerative disorders (ND), one with paraneoplastic
sensory neuropathy associated with anti-Hu antibodies
and a small cell lung carcinoma (sample 9093), and puri-
fied IgGs fractions from one patient with cerebellar ataxia
and anti-Yo antibodies (see above for the purification
method).
Infusion of Ab and microdialysis
Experiments were approved by the Animal Care Com-
mittee of ULB. We made all efforts to reduce animal
suffering as much as possible and to reduce the number
of animals used for the study. Males wistar rats (weight:
240-430 gr) were anaesthetized with chloral hydrate
(400 mg/kg administered ip) prior surgery. Numbers of
rats used for each experiment are indicated in the figure
legends.
Part of the methodology has been reported elsewhere
[5]. Briefly, microdialysis guides (CMA12, CMA, Swe-
den) were inserted in the superior limit of CA1 area and
in the premotor area rFr2 according to the atlas of Paxi-
nos-Watson (see also table 1 the respective sites of
injection for the experiments carried out and the work-
ing hypothesis for each experiment). Coordinates for
CA1 area and rFr2 were (related to bregma): A/P -5.2
mm, Lat 4.5 mm, D/V -2.4 mm, and A/P + 2 mm, Lat 1
mm, D/V -1 mm, respectively. Dental cement was used
to fix the guides on the skull. Rats were anaesthetized
with chloral hydrate (400 mg/kg ip) [5]. We selected
this procedure of continuous anaesthesia because
(a) baseline measurements are more stable due to
absence of interference of voluntary motor activity on
neurotransmission, and (b) we discovered that in vivo
glutamate measurements are highly sensitive to mechan-
ical perturbations that might occur in the environment
when rats hit unexpectedly the sides of the cage or any
structures around. A needle (Hamilton point style 4,
Hamilton) was inserted in the guide. The extremity of
the needle was located between -2.4 and -4.4 mm for
CA1 zone, and between -1 and -2 mm for rFr2 area.
Infusion of antibodies was performed using a micro-
pump (CMA100, CMA, Sweden). Rats were lying over a
temperature regulator (Heating Controller 872/1, Har-
vard apparatus). Indeed, it has been shown that the tem-
perature is a key-factor for NMDA assessments (the
channel kinetics play an important role in determining
amplitude and time course of NMDA receptor-mediated
postsynaptic currents) [6]. Microdialysates were col-
lected every 10 minutes (unless specified). Ringer’s solu-
tion (composed of NaCl 148 mM, CaCl2 1.1 mM, KCl 4
mM; optimized at pH 7.2 with NaHCO3 10 mM) was
used.
The injection procedure itself did not affect the values
of metabolites collected by microdialysis. This was
demonstrated by the following experiment (microdialy-
sates collected every 10 min: 3 basal measurements
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rate of 1 μL/min at + 30 min, followed by 3 measure-
ments post-injection). In 4 rats, the baseline values
(±SD) of extra-cellular glutamate in CA1 zone were:
2.13 ± 0.30 μM at time 10 min, 2.05 ± 0.24 at time + 20
min, 1.95 ± 0.35 μM at time + 30 min, 2.23 ± 0.33 μM
at time + 45 min, 2.13 ± 0.49 μMa tt i m e+5 5m i n ,
1.98 ± 0.43 μM at time + 65 min (analysis of variance:
F = 0.279, p = 0.917).
Analysis of metabolites
Concentrations of glutamate were determined using a
CMA600 device (CMA, Sweden). Linearity regression
coefficient (R
2) determined locally is 0.9984 [7]. The fol-
lowing experiments were conducted:
-Dose-response study
We first determined whether controls’ CSF versus
patients’ CSF modified the extra-cellular concentrations
of glutamate. Following the observation of an increase
in glutamate concentrations with patients’ CSF, we stu-
d i e dt h ed o s er e s p o n s ee f f e c to fo n ep a t i e n t ’sC S F
(9049) using 2 dilutions (half-dose and 1/1). Glutamate
concentrations were determined at baseline and 30 min-
utes following infusion of each dilution. An equilibration
period was used to allow stable baseline measurements.
We confirmed the dose response effect using purified
IgGs at 4 dilutions (1/8, 1/4, 1/2 and 1/1). The volume
injected was 5 μL, with a flow rate of 1 μL/min.
- NMDA and AMPA regulation
The NMDA effect [5,7] was evaluated using the follow-
ing procedure: we first determined the concentrations of
glutamate in 4 successive samples starting 60 minutes
after infusion of a control solution (CSF from neurologi-
cal patients without NMDA-R Ab) or patients’ CSF
(volume of 5 μL; flow rate of 1 μL/min for 5 min). We
subsequently infused NMDA by reverse dialysis (20 mM
dissolved in Ringer solution, infusion flow 1 μL/min)
and measured glutamate in the 4 consecutive samples.
The effect of 2-amino-5-phosphonovaleric acid (APV, a
selective NMDA receptor blocker; 50 μM by reverse dia-
lysis) was evaluated 30 minutes after infusion of a con-
trol solution or patients’ CSF. To assess the interaction
with the AMPA pathway, AMPA and the AMPA
blocker DNQX (6,7-dinitro-quinoxaline-2,3-dione) were
used at doses of 5 mM and 500 μM, respectively [7-9].
AMPA and DNQX were administered 1 hour after the
infusion of the control solution or the patients’ CSF.
AMPA was administered alone and in combination with
NMDA. DNQX was administered either alone or in
combination with NMDA 20 mM.
-Inhibition of glial transport
Since astrocytes play a major role in the removal of glu-
tamate from the extracellular compartment [10], the
effects of the glutamate transport inhibitor L-2,4-trans-
pyrrolidine-dicarboxylate (PDC; 10 mM) were studied to
evaluate the consequences of glial transport inhibition
on the concentrations of glutamate in the extra-cellular
space in presence of NMDA-R Ab. PDC partly mimics
reverse glutamate uptake [11]. PDC was infused after 60
minutes by reverse dialysis, either following the injection
of the control CSF 9093 or following the injection of
patients’ CSF (CSF 9049). The infusion of PDC lasted 10
minutes. We determined the ratios of increase of gluta-
mate concentrations induced by PDC (glutamate con-
centrations post-PDC administration divided by
glutamate concentrations pre-PDC administration).
-Blockade of GABA-A receptors and infusion of GABA
In order to study the effects of blockade of GABA-A
receptors, we infused bicuculline by reverse dialysis in
loco at a concentration of 20 μM during 30 minutes,
after infusion of the control CSF 9093 or the NMDA-R
Ab positive CSF 9049. We determined the concentra-
tions of glutamate before and after blockade of GABA-
A receptors. We also analyzed the effects of infusion of
gamma-aminobutyric acid (GABA; 50 μM) following
pre-administration of pregabalin (a selective blocker of
VGCC) to estimate the rate of sensitivity to GABA
when presynaptic release of glutamate was blocked.





a,b,c CA1 rFr2 NMDA-R Ab impair the glutamate concentrations in the extra-cellular space
NMDA and AMPA regulation
a,b,c,d CA1 NMDA-R Ab impair the NMDA- and AMPA-mediated regulation of glutamate
Inhibition of glial transport
a,b CA1 NMDA-R Ab impair the glial transport of glutamate
Blockade of GABA-A receptors
a,b CA1 Bicuculline enhances the concentrations of glutamate in case of pre-treatment with
NMDA-R Ab
Infusion of GABA
c rFr2 Infusion of GABA decreases the concentrations of glutamate after administration of
pregabalin
Effects on concentrations of nitric oxide
(NO)
a,b
rFr2 NMDA-R Ab increase the concentrations of NO
aUse of controls’ CSF;
bUse of patients’ CSF;
cUse of purified IgG from a patient positive for NMDA-R antibodies;
dUse of purified IgGs from a patient positive for
anti-Yo antibodies.
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sion of purified IgGs (positive for NMDA-R antibodies).
Measurement of nitric oxide (NO)
NO was measured using a selective microsensor (Iso-
NOPF100; Apollo 1000, World Precision Instruments)
inserted near the tip of the cannula at the site of infu-
sion in the brain. Calibration was performed using S-
nitroso-Nacetyl-D,L-penicillamine (SNAP, Sigma) as
reported by Alvarez et al. [12]. We administered 7-
nitroindazole (7-NI), a selective blocker of nNOS, in
order to test the hypothesis that changes in NO concen-
trations were of neuronal origin. 7-NI was infused in
loco during 5 minutes (dose: 200 μM). NO was mea-
sured at baseline, following infusion of a control solu-
tion or CSF with NMDA-R Ab (time T50 to T60), and
following administration of 7-NI (time T60 to T70).
Evaluation of microperfusion
We also assessed the microperfusion in the sites of
injection (CA1, rFr2) using laser Doppler flowmetry
(LDF), in order to confirm that the microperfusion was
preserved during the experiments. A laser flow probe
was inserted near the tip of the microdialysis guide in
order to monitor the blood flow locally in the brain
(Oxylab, Oxford optronix microvascular perfusion moni-
tor). This technique allows the early detection of bleed-
ing (immediate drop in blood flow). The technique has
been first validated in 12 rats. We determined the blood
flow (expressed in arbitrary units BPU - blood per units
- allowing evaluation of relative changes in perfusion at
the beginning and at the end of each experiment [13].
Rats with impaired blood flow were excluded from the
analysis (3 rats with regional blood flow decreasing
below 45% of basal values, whereas the regional blood
flow values remained above 65% of baseline values in all
the other rats for all the experiments performed).
Histological verification
We assessed the localization of the injection site for
each rat on frozen brain sections in a way very similar
t oam e t h o dp r e v i o u s l yp u b l i s h e d[ 1 4 ] .O n l yd a t aw i t h
correct probe location (the exposed dialysis membrane
located in the target region) were analysed (3 rats
excluded). Figure 1 illustrates an example of histological
section at the level of CA1 area.
Statistical analysis
Data were exported to Microsoft Excel. Statistical analy-
sis was performed using Sigma Stat (Jandel Scientific,
Germany). The normality of data was assessed with the
Kolmogorov-Smirnov test, prior selection of parametric
versus non parametric procedures. We applied the
Mann-Whitney rank sum test to compare the concen-
trations of glutamate at baseline (before infusion of
CSF) in the 2 groups (control group versus NMDA-R
Ab-positive group) and to compare the effects of infu-
sion of CSF in the control group and in the NMDA-R
Ab-positive group. For the dose-response study, a linear
regression was computed with 95% confidence and pre-
diction intervals for the NMDA-R Ab-positive group.
To analyse the effects of AMPA, NMDA, APV, AMPA
and DNQX on the concentrations of glutamate, we
applied the analysis of variance on ranks, followed by
the Tukey test. To compare the effects of trans-PDC in
the 2 groups of rats (rats infused with control solution
versus rats infused with NMDA-R Ab), we used the Stu-
dent test. The effects of blockade of GABA-A receptors
on extra-cellular concentrations of glutamate were
assessed with the analysis of variance followed by the
Bonferroni test. A similar procedure was applied to
assess the effects of infusion of GABA after administra-
tion of pregabalin. We used the analysis of variance fol-
lowed by the Tukey test to evaluate the effects of 7-NI
on NO after the infusion of control solution or NMDA-
R Ab.
Results
1. Patients’ CSF increase glutamate concentration in the
extra-cellular space in a dose-dependent manner
Figure 2A illustrates the concentrations of glutamate
measured before and after infusion of controls’ CSF (5
controls’ CSF), patients’ CSF with NMDA-R-Ab (6
patients’ C S F )a n dp u r i f i e dI g G sf r o mo n ep a t i e n tw i t h
NMDA-R-Ab and as control, one patient with Yo-Ab,
respectively. At baseline (before infusion of CSF), con-
centrations of glutamate were similar in the control
group and the patients’ CSF group (mean ± SD: control
group: 2.59 ± 0.45 μM, patients’ CSF group: 2.48 ± 0.60
μM; inter-group difference: p = 0.24). In the control
group, infusion of CSF did not change the concentra-
tions of glutamate measured after infusion as compared
to baseline values before infusion (mean values ± SD
after infusion: 2.61 ± 1.13 μM; infusion effect: p = 0.60).
By contrast, infusion of patients’ CSF with NMDA-R-Ab
and purified IgGs raised significantly the concentrations
of glutamate (mean values ± SD after infusion = 10.87 ±
5.69 μM; infusion effect: p < 0.001). Figure 2B shows
the concentrations of glutamate after infusion for the
subgroups of rats infused with the various CSF (con-
trols’ CSF and patients’ CSF). In addition, the concentra-
tions of glutamate obtained with the purified IgGs are
also shown. Extra-cellular concentrations of glutamate
following infusion of control purified IgGs remained
unchanged (range: 1.91 to 2.79 μM). By contrast, values
of glutamate concentrations following infusion of puri-
fied IgGs from a patient positive for NMDA-R antibo-
dies were extremely high, ranging from 18.4 to 22.6 μM.
Using patient’s CSF 9049 infused in rFr2, or purified
IgGs infused in CA1, a dose response effect was identi-
fied with a linear relationship (Figure 2C; R
2 = 0.976
and 0.953, respectively) between the dilution of patient’
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cellular space (p < 0.001).
2. Patients’ CSF impair NMDA and AMPA-mediated
regulation of glutamate
Administration of NMDA increased the concentrations
of glutamate in case of pre-infusion with control CSF
(from 2.64 ± 0.29 to 8.06 ± 0.76 μM; p < 0.01; Figure 3A)
and the basal extra-cellular concentration of glutamate
was restored by administration of APV, an antagonist of
NMDA-R (2.52 ± 0.12 μM; p = 0.56). NMDA also
increased the extra-cellular concentration of glutamate
after pre-infusion with patients’ CSF (from 9.04 ± 1.05 to
16.45 ± 0.95 μM; p < 0.001) and the glutamate concentra-
tion decreased also by subsequent administration of APV
(10.42 ± 0.63 μM; p < 0.01). However the concentrations
of glutamate were not completely restored by APV, sug-
gesting that NMDA-R-Ab impaired the glutamatergic
transmission also via other receptors than NMDA-R.
Therefore, in order to assess the AMPA pathway we stu-
died the effect of the administration of AMPA and
DNQX (an antagonist of AMPA receptor). Following
infusion of AMPA, extra-cellular levels of glutamate were
2.91 ± 1.71 μM in controls and 8.06 ± 1.97 μMi nt h e
group NMDA-R antibodies (inter-group difference:
p < 0.05; Figure 3B). Interestingly, DNQX had a different
effect in rats pre-infused with controls’ CSF or patients’
CSF. Indeed, when DNQX was administered 1 hour after
controls’ CSF, glutamate concentration increased from
2.64 ± 0.29 to 6.5 ± 0.66 μM .B yc o n t r a s t ,n oe f f e c tw a s
observed when DNQX was administered after patient’s
CSF (9.04 ± 1.05 versus 9.53 ± 1.01 μM) suggesting that
AMPA receptors were deregulated by the presence of
patients’ CSF. NMDA had no effect in presence of
DNQX on glutamate concentration both in control and
patient’s CSF groups. However, the effect of concomitant
administration of NMDA and AMPA was totally differ-
ent in the two groups. In the rats infused with patients’
CSF, a major increase in the concentrations of glutamate
w a so b s e r v e da sc o m p a r e dt or a t si n f u s e dw i t hN M D A
alone (21.85 ± 2.33 versus 16.45 ± 0.95 μM respectively:
p < 0.01). Concomitant administration of AMPA and
NMDA decreased the extra-cellular concentration of glu-
tamate in the control group (8.06 ± 0.76 versus 5.8 ± 0.37
μM: p < 0.05). Taken together, these results indicate that
patients’ CSF modified the balance between AMPA and
NMDA receptors. This is consistent with studies on
AMPA/NMDA ratios indicating that the balance between
these two pathways is required for maintaining physiolo-
gical activities in neuronal networks [15].
Figure 1 Example of histological section at the level of CA1 area after experiment. Location of the guide (G) and tip (T) of the
microdialysis probe in right CA1 of the rat after experiment. Ent: entorhinal cortex; MG: medial geniculate nuclei; MP: medial mammillary
nucleus; fmj: forceps major corpus callosum.
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glutamate
We used the glutamate transport inhibitor L-2,4-trans-
pyrrolidine-dicarboxylate (PDC) [11] to evaluate the possi-
ble role of astrocytes on the increase of glutamate concen-
trations after infusion of patient’s CSF. The percentage of
increase of glutamate concentration induced by the inhibi-
tion of the glial transport of glutamate was similar in rats
infused with control solution (control CSF 9093; increase
to 153.8 ± 14.7% as compared to pre-administration of
CSF; n = 6 sides) and in rats infused with patients’ CSF
(CSF 9049; 156.5 ± 19.7%; n = 6 sides; inter-group differ-
ence: Student test: p = 0,791).
4. Blockade of GABA-A receptors increases the
concentrations of glutamate and infusion of GABA
reduces the levels of glutamate after blockade of VGCC
Infusion of bicuculline, an antagonist of GABA-A recep-
tors, increased the levels of glutamate both in case of infu-
sion of control CSF and following infusion of patients’
Figure 2 Effects on extra-cellular concentrations of glutamate. A: comparison of the glutamate concentrations measured before (basal) and
after infusion of CSF or purified IgGs of patients (Post-Inf.). Each sample (5 control CSF, 6 patients’ CSF with NMDA-R-Ab, one purified IgGs positive
for NMDA-R-Ab and one purified IgGs positive for anti-Yo antibodies) was infused in 4 different rats. Means and SDs are represented. Measurements
were made at baseline (before infusion), and between 30 and 60 minutes after CSF or purified IgGs infusion. B: point plot (one point corresponds
to one rat injected) of the extra-cellular concentrations of glutamate following infusion of CSF (open circles: controls’ CSF; filled circles: patients’
CSF), and purified IgGs (open circles: control IgGs from a patient with Yo-Ab; filled circles: purified IgGs from a patient positive for NMDA-R-Ab)
measured in CA1 zone between 30 and 60 minutes after CSF infusion. C: Top panel: concentrations of extra-cellular glutamate according to the
dilution of patients’ CSF infused in the CA1 area. Four rats were infused with 3 successive doses from one patient’s CSF positive for NMDA-R-Ab
(CSF 9049). Linear regression, 95% confidence intervals (dashed lines) and 95% prediction intervals (dotted lines) are shown. Bottom panel: Similar
results were obtained with purified IgG of CSF 9052. Four rats were individually infused with 4 successive doses. **: p < 0.01.
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of glutamate. Groups 1 and 2: n = 8 rats injected with 5 control CSF. Groups 3 and 4: n = 8 rats injected with CSF from 5 patients positive for
NMDA-R-Ab. Groups 5 and 6: 4 rats injected with a control CSF and 4 rats injected with one CSF positive for NMDA-R-Ab, respectively. Values are
mean ± SEM. B: Effects of AMPA, AMPA blockade (DNQX), combination of NMDA + DNQX and combination of NMDA + AMPA following
administration of NMDA-R-Ab. Groups 1, 3 and 5: 4 rats injected with 4 control CSF. Groups 2, 4 and 6: 4 rats injected with CSF from 4 patients
with NMDA-R-Ab. Group 7: 4 rats injected with 1 control CSF. Group 8: 4 rats injected with 1 CSF with NMDA-R-Ab. Values are mean ± SEM. *:
p < 0.05; **: p < 0.01
Manto et al. Orphanet Journal of Rare Diseases 2010, 5:31
http://www.ojrd.com/content/5/1/31
Page 7 of 12CSF 9049 (Figure 4A; p < 0.001). However, the increase in
the group administered with patients’ CSF was signifi-
cantly higher as compared to the increase in the control
group, indicating a vulnerability to blockade of GABA-A
receptors (group by time interaction: p < 0.001).
For the study on the effects of infusion of GABA, we
first confirmed that extra-cellular concentrations of
glutamate raised dramatically following infusion of puri-
fied IgGs (NMDA-R Ab effect: p < 0.001; Figure 4B).
We found that subsequent administration of pregabalin
decreased significantly the extra-cellular concentration
of glutamate from 20.45 ± 1.81 μMt o9 . 8 3±2 , 4 8μM
(drop of about 52%; pregabalin effect: p < 0.01). Post-
infusion of GABA 50 μM reduced the concentrations of
Figure 4 Interaction with GABA-A receptors and infusion of GABA. A: Effects of blockade of GABA-A receptors on glutamate levels
following infusion of patients’ CSF. In rats infused (INF) with CSF with NMDA-R-Ab (9049; n = 3 rats; grey bars), administration of bicuculline
(represented by a hatched rectangle) increased markedly the concentrations of glutamate. The bicuculline-induced increase of glutamate was
lower in rats injected with the control solution 9093 (n = 3 rats; white bars). B: Effects of successive administration of pregabalin (PG) and GABA
after infusion of purified IgGs of a patient with NMDA-R-Ab (n = 4 rats). Concentrations of glutamate raised markedly with purified IgGs. Basal: T0
min; Post-NMDA-R-Ab (Post-CSF): post-injection at T30 min; Post-PGB: T90 min post-infusion; Post-Gaba: Post-infusion of Gaba 50 μM at T120
min. Values are mean ± SD. **: p < 0.01
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of about 28% as compared to the concentration obtained
after infusion of purified IgGs; GABA effect: p < 0.05).
These data showed that GABA still reduced the levels of
glutamate even after blockade of pre-synaptic alpha-2-
delta subunit of VGCC.
4. Patients’ CSF increase NO concentrations
Patients’ CSF raised the concentrations of NO as com-
pared to the control solution (p < 0.01; Figure 5).
Administration of 7-NI reduced significantly the levels
of NO in rats infused with patients’ CSF (p < 0.01),
arguing for a neuronal origin for the raise in NO
concentrations.
Discussion
The main finding of this study is that patients’ CSF alter
the extracellular levels of glutamate, suggesting an
impairment of the glutamatergic transmission and indu-
cing a susceptibility to AMPA infusion. These results
suggest that by decreasing the levels or blocking the
extracellular epitopes of the NR1 subunit of the
NMDA-R, patients’ antibodies induce a hyperglutama-
tergic state in the brain with an imbalance between
NMDA and AMPA pathways. This is the first in vivo
demonstration that an antibody targeting NMDA recep-
tors puts the brain circuitry in an AMPA-dependent
hyperglutamatergic state. Previous studies have shown
that extra-cellular levels of glutamate increase in pre-
sence of antibodies targeting glutamic acid decarboxy-
lase (GAD enzyme catalyzing the conversion of glutamic
acid into GABA) [5]. Therefore, the increase of extra-
cellular levels of glutamate is not specific of NMDA-R
antibodies.
Effects on extra-cellular glutamate
In presence of patients’ CSF and purified IgGs, very high
concentrations of glutamate were found in the extra-cel-
lular space during NMDA infusion. This is consistent
with a dysfunction of the NMDA-related glutamatergic
turn-over or an impaired turn-over of receptors, leading
to NMDA-related excitotoxicity [5,8,16-18]. Concomi-
tant administration of NMDA and AMPA induced a
rise in the extra-cellular concentrations of glutamate up
Figure 5 Effects of patient’s CSF on concentrations of nitric oxide (NO). Inhibition of nNOS with 7-nitroindazole (7-NI) counteracts the
effects of NMDA-R Ab. N = 4 rats infused with control CSF 9093 and n = 4 rats infused with a CSF with NMDA-R-Ab (9049). Values are
mean ± SD and are expressed as percentages of baseline measurements. **: p < 0.01
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of glutamate impair the excitability of neuronal net-
works. The delayed excitotoxic neuronal dysfunction or
neuronal death after exposure to high glutamate con-
centrations appears to play an important role in several
neurological disorders [18,19]. Given the key-roles of
NMDA receptors in mediating excitatory transmission,
an excitotoxic cascade is likely to be triggered at the
concentrations found in the present study. In vulnerable
neurons, excitotoxic insult induces a sustained positive
feedback loop between NMDA-R-dependent current
and depolarization-mediated glutamate release, which
drives Ca++ elevation and delayed excitotoxicity. We
suggest that the balance between AMPA receptors and
NMDA receptors might be a key-element for the regula-
tion of glutamatergic neurotransmission in vivo. This is
consistent with recent studies on AMPA/NMDA ratios
[15]. Fast glutamatergic signalling might be at a com-
pensatory stage or trafficking might be altered by
NMDA-R Ab. Indeed, it has been demonstrated that
blockade of NMDA-R might stop the AMPA-R endocy-
tosis [20]. However, it should be kept in mind that the
NMDA-R-Ab have been shown to cause a reversible
reduction of the post-synaptic NMDA-R density as well
as NMDA-R-mediated currents in vitro, so that high
levels of glutamate may not result in cell death, as sug-
gested by the relative preservation of neurons in autopsy
studies and by the reversibility of brain atrophy in severe
cases who survived [21]. It is possible that the levels of
glutamate in human brain in presence of NMDA-R-Ab
do not reach the synaptic threshold necessary to induce
a genuine neurodegeneration through the overactivation
of AMPA receptors [17].
Although molecular and electrophysiological studies
showed that patients’ NMDA-R-Ab did not alter the
density of synaptic AMPA receptors and AMPA recep-
tor mediated currents in vitro and after infusion of anti-
bodies into the hippocampus of rodents [4], data from
the current study suggests that networks of neurons and
inhibitory interneurons might be required to observe
the imbalance between NMDA and AMPA pathways.
Moreover, the current data likely reflects the fact that
AMPA receptors are very mobile in the cytoplasmic
membrane and microdialysis assesses also extra-synaptic
compartments of glutamatergic synapses. About 50% of
synaptic AMPA receptors are exchanged with extra-
synaptic AMPA receptors in a few minutes [22].
Findings from this study correlate symptoms of ence-
phalitis with NMDA-R-Ab at early stages of the disease,
including anxiety, agitation and seizures, although some
of these symptoms re-emerge during the phase of recov-
ery. Furthermore, the excitotoxicity caused by high
levels of glutamate may account by the irreversibility of
symptoms of some patients. Taken together with studies
examining the cellular and synaptic effects of patients’
antibodies [4], the current work reveals a novel mechan-
ism of hyperglutamatergic state in the brain circuitry
induced by antibodies.
Figure 6 Proposed scheme of the synaptic consequences of NMDA-R-Ab. The antibodies block the NR1/NR2 heteromers of the NMDA
receptor, causing a state of imbalance between NMDA and AMPA receptors. Blockade of NMDA-R impairs AMPA-R endocytosis. NMDA-R-Ab
cause an increased release of glutamate which is dependent on the alpha2-delta subunit of VGCC and which is also related to a deregulation of
gabaergic interneurons. NO acts as a retrograde messenger and amplifies glutamate release.
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We suggest the following scheme of the effects of
NMDA-R-Ab on glutamatergic synapses to summarize
our findings (Figure 6). NMDA-R Ab block the NMDA-
R not only at the post-synaptic level of the glutamater-
gic synapse, but also at the level of inhibitory gabaergic
interneurons, a factor which contributes to the hyper-
glutamatergic state. The consequence of the fixation of
NMDA-R-Ab to post-synaptic NMDA receptors is an
imbalance NMDA/AMPA, rendering the post-synaptic
element particularly vulnerable to administration of
AMPA. Dysfunction of gabaergic interneurons results in
a disinhibition of glutamatergic neurons, causing
increased concentrations of glutamate and enhancing
the excitability of neurons. The increase in NO concen-
trations participates in the glutamate release. Indeed,
NO is a diffusible messenger which modulates synaptic
transmission [23]. NO is known to act as a retrograde
messenger and can amplify glutamate release [24].
Potential implications
There are several potential clinical implications from
this study. First, AMPA agonists might have deleterious
consequences for patients. Second, the current results
provide a rationale for evaluating treatments based upon
AMPA antagonists in the acute phase of the disease.
Third, the data robustly support an antibody-mediated
pathogenesis of NMDA-R-Ab in patients’ encephalitis
[4,25], in agreement with clinical experience that shows
that immunotherapy aimed to eliminate circulating anti-
bodies is often effective. Overall, this study highlights
that the encephalitis associated with NMDA-R antibo-
dies is an auto-immune synaptic disorder.
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